Health

Lunit Accelerates Expansion Across Middle East by Bringing AI Solution to Dr. Sulaiman Al Habib Medical Group, Middle East's Largest Healthcare Provider

Lunit strengthens presence in the Middle East by supplying AI-powered breast screening solution to Dr. Sulaiman Al Habib Medical Group for the next three years SEOUL, South Korea, July 26, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnosti...

2023-07-26 14:00 1471

China's Yunhong Group furthers global push on full biodegradation

WUXUE, China, July 26, 2023 /PRNewswire/ -- Recently, the economic representative office ofGuinea-Bissau was unveiled in the pan-health industrial park of Yunhong Group in Wuxue City in centralChina's Hubei Province. The company and representatives of African countries reached a series of cooper...

2023-07-26 13:07 1650

Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023

SHANGHAI, July 25, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical trial data from phase I/II study for advanced solid tumor of Nectin-4-targeting ADC (9MW2821), and phase III study of Long-Acting Recombinant Hu...

2023-07-26 00:00 1818

HaemaLogiX and Peter MacCallum Cancer Centre Announce Myeloma CAR-T Phase I Clinical Trial Agreement

* HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's CAR-T cell therapy in patients with kappa-type myeloma * The agreement is the culmination of previous preclinical research collaboration b...

2023-07-25 19:30 1247

Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023

TAIPEI, July 25, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company has been selected for a late-breaking oral presentation on the positive primary outcomes of its aderamastat (FP-025) Phase 2 proof-of-concept allergic asthma study at the Euro...

2023-07-25 15:19 1804

Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial

SYDNEY, July 24, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the Phas...

2023-07-24 21:02 1739

BreathMo®: The New Generation ECMO system Revealed at ASAIO Conference

SUZHOU, China, July 22, 2023 /PRNewswire/ -- Last month, the American Society for Artificial Internal Organs (ASAIO) 68th Annual Meeting  was successfully held in San Francisco. magAssist's product, BreathMo® was highlighted in the meeting. Dr. Dong Gu...

2023-07-22 17:50 2378

Medlinker's MedGPT Performs 96% As Well As Top Human Doctors

In a Livestreamed Real-World Assessment, MedGPT's AI Doctors Rival Diagnostic Accuracy ofChina's Leading Doctors BEIJING, July 22, 2023 /PRNewswire/ -- Medlinker, a leading digital healthcare company inChina, undertook a real world comparison of AI doctors accessible through its MedGPT service ...

2023-07-22 12:30 3324

YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023

GAITHERSBURG, Md., July 21, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-07-22 04:30 4326

Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

SHANGHAI, July 21, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the National Medical Products Administration (NMPA). 7MW3711...

2023-07-22 00:00 4335

SunHo Announces First Patient Dosed in Phase I/II Clinical Trial of a Potential First-in-class Immunocytokine IBB0979

NANJING, China, July 21, 2023 /PRNewswire/ -- SunHo BioPharmaceutical Co., Ltd. ("SunHo"), a clinical-stage leading biopharmaceutical company in immunocytokines with full-set of capabilities from discovery to commercialization, announced that IBB0979 (B7H3-IL10 immunocytokine), a potential first...

2023-07-21 22:51 2923

GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent

* Striving to further expand its territory to Africa and the Middle East from Southeast Asia and Latin America * "Will create synergy between international procurement market and private markets of individual countries so as to boost sales and profitability" YONGIN, South Korea, July 21, 2023...

2023-07-21 16:47 1964

Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference

BEIJING and SHANGHAI and BOSTON, July 20, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, is pleased to announce today that the company will present its clinical results in the form of Proffered Paper presentation at the 2023 Europ...

2023-07-21 10:19 1859

US FDA Grants Orphan Drug Designation of SN Bioscience's Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung Cancer

SEONGNAM, South Korea, July 20, 2023 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced onJuly 19 that the US FDA had granted an orphan drug designation for small cell lung cancer for SNB-101 (API: SN-38), a new polymer nanoparticle drug under development. SNB-101 is the world...

2023-07-21 08:15 1873

Angel Yeast Highlights Sustainable Protein and Natural Taste Solutions at IFT FIRST 2023

CHICAGO, July 20, 2023 /PRNewswire/ -- Angel Yeast (SHA:600298), a premier global yeast company, showcased its sustainable yeast protein and compound seasoning solutions at the annual expo of the Institute of Food Technologists ("IFT FIRST 2023"), inChicago, that took...

2023-07-20 20:00 2345

BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial

WUXI, China, July 19, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders, today announced the dosing of the first patient in a Phase 1a/1b...

2023-07-20 10:41 1915

Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech

ZHUHAI, China, July 19, 2023 /PRNewswire/ -- Biotheus Inc. ("Biotheus"), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, announced today that it has entered into a strategic research collaboration, option and worldwi...

2023-07-20 09:01 1882

Origin Agritech Secures RMB 2 Million Grant for Building Germplasm Bank in Xinjiang

BEIJING, July 19, 2023 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, announced today that it has been awarded a grant ofRMB 2 million (approximately $280,000 USD) from the Xinjiang government. The grant aims to support Origin's...

2023-07-19 23:54 5284

VARON Launches the Game-changer in the Field--New VP Series Portable Oxygen Concentrator with Increased Mobility and Convenience

SEATTLE, July 19, 2023 /PRNewswire/ -- VARON, a leading oxygen concentrator manufacturer, is proud to announce the launch of a new member of the VP series --VP-2 . This portable oxygen concentrat...

2023-07-19 22:30 1629

JX Luxventure announces a new Artificial Intelligence initiative: USD1,000,000 Agreement with Tianjin Baixing Pharmaceutical Wholesale Co., Ltd. in connection with incorporating ChatGPT type technology for ERP platform

HAIKOU, China, July 19, 2023 /PRNewswire/ -- JX Luxventure Limited (Nasdaq: JXJT) (the "Company"), a company that engages in tourism with business segments covering tourism, tourism duty-free cross-border merchandise and tourism technology solutions, today announced that onJuly 17, 2023, its subs...

2023-07-19 21:36 6762
1 ... 73747576777879 ... 273